Mesoblast Limited (NASDAQ:MESO) Shares Sold by Lazari Capital Management Inc.

Lazari Capital Management Inc. reduced its position in Mesoblast Limited (NASDAQ:MESO) by 15.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 45,467 shares of the company’s stock after selling 8,000 shares during the period. Lazari Capital Management Inc.’s holdings in Mesoblast were worth $371,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Chase Investment Counsel Corp purchased a new position in shares of Mesoblast in the 1st quarter worth about $298,000. GAMMA Investing LLC increased its position in Mesoblast by 50.1% during the 2nd quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after purchasing an additional 1,663 shares in the last quarter. Perkins Coie Trust Co purchased a new position in Mesoblast in the second quarter valued at approximately $68,000. Chapin Davis Inc. lifted its position in Mesoblast by 50.0% during the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after buying an additional 5,000 shares in the last quarter. Finally, Pine Valley Investments Ltd Liability Co purchased a new stake in Mesoblast during the second quarter worth approximately $80,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Stock Down 2.2 %

Shares of Mesoblast stock opened at $9.44 on Wednesday. Mesoblast Limited has a 1-year low of $1.61 and a 1-year high of $11.05. The company has a market capitalization of $1.08 billion, a PE ratio of -8.42 and a beta of 3.47. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The business has a 50-day moving average of $7.55 and a 200-day moving average of $7.16.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on MESO shares. Piper Sandler raised shares of Mesoblast from a “neutral” rating to an “overweight” rating and raised their target price for the company from $4.00 to $11.00 in a research note on Tuesday, July 23rd. Jefferies Financial Group upgraded Mesoblast from a “hold” rating to a “buy” rating in a research note on Thursday, August 29th. StockNews.com lowered Mesoblast from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a research report on Thursday, August 29th. Finally, Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $11.50.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.